文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠道微生物群和氧化三甲胺在心血管疾病中的作用。

The Role of Gut Microbiota and Trimethylamine N-oxide in Cardiovascular Diseases.

机构信息

Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Yanchang RD. 301, Shanghai, 200072, China.

Medical College, Anhui University of Science and Technology, Huainan, China.

出版信息

J Cardiovasc Transl Res. 2023 Jun;16(3):581-589. doi: 10.1007/s12265-022-10330-0. Epub 2022 Oct 17.


DOI:10.1007/s12265-022-10330-0
PMID:36251229
Abstract

Changes in the intestinal flora and its metabolites have been associated with cardiovascular disease (CVD). Short-chain fatty acids, bile acids, and especially trimethylamine N-oxide (TMAO), an endothelial toxic factor produced by gut microbiota from phosphatidylcholine in meat, have been identified to be closely related to endothelial cell dysfunction as well as tightly affiliated with CVD, the two main types being coronary artery disease (CAD) and coronary microvascular disease (CMVD). We discuss how changes in the gut flora and the metabolite TMAO contribute to the development of CAD and CMVD. The above insight might serve as a stepping stone for novel CAD and CMVD diagnostics and therapies centered on microbiota.

摘要

肠道菌群及其代谢物的变化与心血管疾病(CVD)有关。短链脂肪酸、胆汁酸,特别是三甲胺 N-氧化物(TMAO),一种由肠道微生物从肉类中的卵磷脂产生的内皮毒性因子,被认为与内皮细胞功能障碍密切相关,并与 CVD 密切相关,其中两种主要类型是冠心病(CAD)和冠状动脉微血管疾病(CMVD)。我们讨论了肠道菌群的变化和代谢物 TMAO 如何导致 CAD 和 CMVD 的发展。这一见解可能为以微生物群为中心的新型 CAD 和 CMVD 诊断和治疗提供一个切入点。

相似文献

[1]
The Role of Gut Microbiota and Trimethylamine N-oxide in Cardiovascular Diseases.

J Cardiovasc Transl Res. 2023-6

[2]
[Gut microbiota and its metabolite trimethylamine-N-oxide (TMAO): a novel regulator in coronary artery disease].

Sheng Wu Gong Cheng Xue Bao. 2021-11-25

[3]
Intestinal Microbiota-Generated Metabolite Trimethylamine-N-Oxide and 5-Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE-Like Patient Cohort.

J Am Heart Assoc. 2016-6-10

[4]
Gut microbiota-derived trimethylamine-N-oxide: A bridge between dietary fatty acid and cardiovascular disease?

Food Res Int. 2020-12

[5]
Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD).

Clin Res Cardiol. 2022-6

[6]
The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.

Front Endocrinol (Lausanne). 2023

[7]
Trimethylamine N-oxide in cardiovascular disease.

Adv Clin Exp Med. 2022-8

[8]
Gut Microbiota and Cardiovascular Disease.

Circ Res. 2020-7-31

[9]
Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy.

Pharmacol Ther. 2020-9

[10]
Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases.

Cardiovasc Toxicol. 2021-8

引用本文的文献

[1]
Research Trends and Hotspots of Gut Microbiota and Its Metabolites in Cardiovascular Diseases: A Bibliometric Analysis.

J Multidiscip Healthc. 2025-8-21

[2]
Probiotics and Prebiotics in Post-Myocardial Infarction Rehabilitation: Mechanisms, Benefits, and Future Directions.

Curr Nutr Rep. 2025-6-28

[3]
Cardiovascular Disease Risk in Women with Menopause.

J Clin Med. 2025-5-23

[4]
The gut-heart axis: unveiling the roles of gut microbiota in cardiovascular diseases.

Front Cardiovasc Med. 2025-5-26

[5]
Molecular Mechanisms of Type 2 Diabetes-Related Heart Disease and Therapeutic Insights.

Int J Mol Sci. 2025-5-9

[6]
Exploring the gut-heart axis: A prospective analysis of microbiota in cardiovascular health.

Bioinformation. 2024-12-31

[7]
Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.

World J Cardiol. 2025-2-26

[8]
Gut microbiome and inflammation in cardiovascular drug response: trends in therapeutic success and commercial focus.

Inflammopharmacology. 2025-1

[9]
Bacterial live therapeutics for human diseases.

Mol Syst Biol. 2024-12

[10]
Low-Molecular-Weight Compounds Produced by the Intestinal Microbiota and Cardiovascular Disease.

Int J Mol Sci. 2024-9-27

本文引用的文献

[1]
PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction.

Life (Basel). 2022-1-27

[2]
A benzoxazole derivative as an inhibitor of anaerobic choline metabolism by human gut microbiota.

RSC Med Chem. 2020-8-28

[3]
Toll-Like Receptors Regulate the Development and Progression of Renal Diseases.

Kidney Dis (Basel). 2021-1

[4]
Gut microbiota derived trimethylamine N-oxide (TMAO) detection through molecularly imprinted polymer based sensor.

Sci Rep. 2021-1-14

[5]
Discovery of a Histidine-Based Scaffold as an Inhibitor of Gut Microbial Choline Trimethylamine-Lyase.

ChemMedChem. 2020-12-3

[6]
Endothelial dysfunction in patients with myocardial ischemia or infarction and nonobstructive coronary arteries.

J Clin Ultrasound. 2021-5

[7]
Peptidomimetic-based approach toward inhibitors of microbial trimethylamine lyases.

Chem Biol Drug Des. 2021-2

[8]
Gut Microbiota and Cardiovascular Disease.

Circ Res. 2020-7-31

[9]
Gut microbiota and cardiovascular disease: opportunities and challenges.

Microbiome. 2020-3-14

[10]
The role of diet and intestinal microbiota in the development of metabolic syndrome.

J Nutr Biochem. 2019-4-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索